Spontaneous leaflet fracture resulting in embolization from mechanical valve prostheses

Gijs G.J. van Steenbergen MD | Queeny H.Y. Tsang MD | Stefan M. van der Heide MD | Michel W.A. Verkroost MD | Wilson W.L. Li MD | Wim J. Morshuis MD, PhD

Abstract
Spontaneous leaflet fracture of mechanical heart valve prostheses is very rare. We describe a case of spontaneous leaflet embolization 31 years after aortic valve replacement with an Edwards-Duromedics prosthesis (Baxter Healthcare Corp., Edwards Division, Santa Ana, CA). We review the literature on this subject to increase awareness and recognition for this potentially life-threatening complication.

KEYWORDS
aortic valve replacement, Bjork Shiley, HFPF, cavitation, Edwards Duromedics, emergency surgery, leaflet escape, valve failure

1 | INTRODUCTION
Spontaneous leaflet fracture of mechanical heart valve prostheses is very rare. It is potentially life threatening and usually requires emergent surgery. There are a few valve prosthesis series well-known for having a higher risk of such mechanical structural valve failure, of which the Björk-Shiley convexoconcave (BSCC) monostrut tilting disc prosthetic aortic heart valve (Pfizer, Rye Brook, NY) is the most documented. Fractures of the BSCC valve’s outlet struts and subsequent escape of the disc was estimated at 0.7% for all BSCC valves, but was up to 3.9% for the 70° opening angle model, often leading to massive regurgitation and death. Unfortunately, besides the BSCC valve, there are other mechanical heart valve prosthesis brands that have an increased risk of mechanical structural valve failure. We report a case of spontaneous leaflet fracture and escape 31 years after aortic valve replacement with an Edwards-Duromedics (ED) bileaflet mechanical prosthesis (Baxter Healthcare Corp., Edwards Division, Santa Ana, CA) in a 63-year-old male who developed life-threatening acute aortic regurgitation in whom emergent surgical treatment was necessary. To the best of our knowledge, this case presents the longest period between prosthesis implantation and leaflet escape. In addition, a review of the available literature on this subject is presented.

2 | PATIENT PROFILE
A 63-year-old male presented to a local hospital with cardiogenic shock. His previous medical history included endocarditis 31 years ago for which he underwent antibiotic treatment and aortic valve replacement with a 27-mm ED bileaflet mechanical prosthesis. A computed tomography (CT) of thorax and abdomen showed a saccular aneurysm of the ascending aorta measuring 83 × 47 mm (at the level of the previous aortotomy), and changes consistent with pulmonary edema. Coronary angiography (CAG) demonstrated no coronary abnormalities; however, it confirmed severe aortic
regurgitation and the absence of one leaflet of the mechanic aortic valve prosthesis (Figure 1A). Subsequent echocardiography confirmed a severe aortic regurgitation with preserved left ventricular function (Figure 1B). The patient was intubated and transferred to our center for emergent operative therapy.

During induction of anesthesia, the patient went into cardiac arrest and emergent surgery was performed and cardiopulmonary bypass (CPB) was initiated with cannulation of the left femoral artery and vein. A median sternotomy was performed and the distal ascending aorta was crossclamped and the heart arrested with cold antegrade Custodiol cardioplegia (Dr. Franz Köhler Chemie GmbH, Bensheim, Germany). Inspection of the mechanical aortic valve prosthesis confirmed a missing prosthetic leaflet (Figure 2), without signs of pannus, paravalvular leakage, or thrombus formation. The valve prosthesis and diseased ascending aorta and aortic root were excised and replaced with a 2-mm Perimount Magna Ease biological aortic valve (Edwards Lifesciences®, Irvine, CA) and a vascular graft (Vascutek® Gelweave prosthesis Ø 32 mm, Terumo Cardiovascular Group, Ann Arbor, MI), with reimplantation of the coronary ostia. The patient was weaned from CPB and the arterial and venous canula were removed. Duration of aortic crossclamping was 93 min and total CPB time was 178 min. A 3D reconstruction of the previously made CT revealed the missing leaflet to be located in the left superficial femoral artery (Figures 3A and 3B). Postoperative, an additional CT scan located the other one-third of the leaflet in the left popliteal artery. Removal was not indicated due to the non-occlusive position of the leaflet and normal ankle-brachial pressure index of 1.1. After discharge the patient received warfarin to prevent thrombotic complications of the remaining leaflet fragment. The patient made an uneventful recovery and remains asymptomatic one year following surgery.

3 INCIDENCE AND OUTCOMES FOLLOWING MECHANICAL VALVE STRUT FRACTURES

As mentioned earlier, the BSCC valve is the most well-known example of mechanical structural heart valve failure, associated with more known serious adverse outcomes than any other implanted medical device. Following its introduction in 1979, by 2003 >600 cases were known to have valve fractures, often leading to sudden cardiac deaths. In addition to the BSCC valve, there are other valves that carry a higher risk for leaflet fracture and subsequent leaflet escape, of which the most prominent is the ED prosthesis (as illustrated by our case), followed by the TRI Technologies (TRI Technologies Prosthetic Heart Valve, Ltda, Belo Horizonte, Brazil) mechanical valve.

The ED prosthesis (Baxter Healthcare Corp., Edwards Division) is a bileaflet mechanical heart valve first introduced and implanted in 1982. After approximately 20,000 valve prostheses were implanted the valve was withdrawn from the market in 1988 after at least 46 cases of leaflet escape were registered by the manufacturer. The original valve was modified to correct structural problems and was reintroduced in 1990 as the Edwards TEKNA bileaflet valve. However, despite the revisions to the valve, cases of leaflet escape continued which led to the discontinuation of the TEKNA valve in 2000.

Twenty-one papers reporting 23 cases involving ED or Edwards TEKNA valves were published after discontinuation (Table 1). In these cases, fractured leaflets occured more commonly from mechanical mitral valves compared to aortic valves (87% vs 13%). This is attributed to differences in dynamics and pressures over the mitral valve compared to protheses in the aortic position. Duration between prosthesis implantation and leaflet escape varies among cases. The mean period from initial surgery until leaflet escape is 9.1 ± 7.4 years for mitral valves (n = 19) and 4.5 ± 3.1 years for aortic valves (n = 3, P = 0.908). Our current case, which is 31 years between initial surgery and leaflet escape, is the longest period between valve implantation and the event. Patients tend to present with acute severe dyspnea due to fulminant pulmonary edema and left-sided cardiac dysfunction. All patients underwent emergency surgery. Four patients did not survive acute cardiac decompensation or emergency surgery, and the mortality rate is estimated at 17% among published cases (Table 2).

Leaflet escape in mechanical heart valves of other manufactures is very rare and is limited to single case reports, including an Omnicarbon aortic valve prosthesis (Medical Inc., Inver Grove...
FIGURE 2  Mechanic aortic valve with missing leaflet in anatomic position (A) and after removal (B)

FIGURE 3  Localization of missing leaflet on computed tomography (A and B). Two-third of the leaflet was recovered (C) from the deep femoral arteries
Heights, MN), a St. Jude mitral valve prosthesis31 (St. Jude Medical, St Paul, MN), and an On-X mitral valve prosthesis32 (Medical Carbon Research Institute, Austin, TX). Similar to the ED valve, patients present with cardiac failure and emergency surgery was performed in all cases (Table 3).

### 4 DIAGNOSIS OF LEAFLET FRACTURE AND ESCAPE

Transthoracic echocardiography is used to diagnose a missing leaflet.14,26,27 Transthoracic echocardiography in our case showed major aortic regurgitation but did not clearly identify the missing leaflet. We diagnosed the missing aortic valve leaflet using fluoroscopy while performing CAG. The radio-opacity of the carbon that is used to design mechanic heart valves makes it very easy to observe the absence of simultaneous movement of leaflets or a stenotic valve by leaflet immobility (Figure 2). Fluoroscopy could therefore be a valuable alternative to trans-thoracic echocardiography when imaging with echocardiography is difficult such in obese patients.

Computer tomography is a reliable imaging technique to localize escaped leaflets. In our review of the ED and/or Edwards TEKNA valves, most leaflets migrated to the abdominal aorta (13%) or iliac arteries (78%), and in one case to the brachiocephalic artery (Table 1).25 In 48% of cases a leaflet fracture was demonstrated (Table 1). Other valve brands show similar locations for leaflet embolization (Table 3).

Our patient also had a fragmented leaflet, of which 2/3 of the leaflet was located in left superficial femoral artery and 1/3 in the left popliteal artery (Figure 3). In cases where the escaped leaflet is still missing or fragmentation is suspected, we recommend to perform a full-body CT, preferably with 3D reconstruction.
purpose of identifying valve prostheses that are high-risk for structural deterioration. Investigation into cases with valves other than the ED valve revealed significant tab malalignment and asymmetry in the TRI Tech valves in which tab fracture and leaflet escape had occurred. Similar to the ED valve, valve analysis of fractured leaflets showed cavitation as the main contributing factor to valve failure and leaflet escape.

### 6 | INDICATIONS FOR PROPHYLACTIC REOPERATIVE VALVE REPLACEMENT?

In the BSCC cases a Dutch research group showed that the 70° opening angle, large valve size, mitral position and young age were the most important determinants for risk of outlet strut fracture (OSF). Furthermore, analysis of manufacturers data showed that several aspects of the manufacturing process (eg, repetitive testing) also increased the risk of outlet strut fractures. Based on these risk factors, advisory algorithms were devised to aid cardiothoracic surgeons in making a case-to-case decision on prophylactic BSCC replacement. It was concluded that each case should be assessed individually for a proper balance between surgical mortality and gain in life expectancy after reoperation, against the risk of OSF and subsequent loss of life expectancy. Fortunately, the majority of the BSCC patients are now over 70 years of age and the annual incidence of OSF is estimated between 0.02% and 0.04% annually.

These indications for elective prophylactic reoperation can be extrapolated to patients with ED or TRI Technologies valves. Each case should be examined individually, and operative risk should be assessed compared to the risk of leaflet escape. Some clinics have offered prophylactic reoperations in asymptomatic patients to replace the TRI Technologies valve with excellent results. In one series, operative mortality was 0% in 22 patients and none of these patients experienced permanent complications. Nevertheless, in contrast

| Valve type       | (First) author, year of publication | Patient count | Position | Duration to escape in years | Cardiogenic shock | Emergency surgery | Alive | Fragmented leaflet | Location of leaflet |
|------------------|-----------------------------------|---------------|----------|-----------------------------|-------------------|-------------------|-------|-------------------|-------------------|
| TRI-Technologies | Bottio et al.²                     | 1             | Aortic   | 0.03                        | NR                | −                 | −     | −                 | AA                |
|                  |                                    | 2             | Mitral   | 1.66                        | NR                | +                 | +     | −                 | AA                |
|                  | Dikmengil et al.²                  | 3             | Mitral   | 0.33                        | +                 | +                 | −     | −                 | AA                |
|                  | Gerosa et al.⁴                     | 4             | Aortic   | NR                          | −                 | −                 | −     | −                 | IFA               |
|                  | Cianciulli et al.⁵                 | 5             | Mitral   | 3                           | −                 | +                 | +     | NR                | NR                |
|                  | Zhang et al.⁶                      | 6             | Mitral   | 3                           | +                 | +                 | −     | −                 | AA                |
|                  | Barbera et al.⁷                    | 7             | Mitral   | NR                          | +                 | NR                | −     | −                 | NR                |
|                  |                                    | 8             | Aortic   | NR                          | −                 | −                 | −     | NR                | NR                |
|                  |                                    | 9             | Aortic   | NR                          | −                 | −                 | −     | NR                | NR                |
| Omnicarbon       | Komberg et al.³⁰                   | 12            | Aortic   | 3.5                         | +                 | +                 | −     | −                 | AA                |
| St Jude          | Moster et al.³¹                    | 10            | Mitral   | 1.5                         | +                 | +                 | NR    | +                 | IFA               |
| On-X             | Kageyama et al.³²                  | 11            | Mitral   | 5                           | +                 | −                 | −     | −                 | AA                |

AA, abdominal aorta; IFA, Ileofemoral arteries; NR, not reported.
to the large amount of data available for the BSCC cases, there is unfortunately no literature available in which large cohorts are analyzed and thoroughly examined for risk factors for leaflet fracture and escape in patients with ED or TRI Technologies valves. The incidence of BSCC leaflet fracture by far exceeds the amount of cases published on ED leaflet escape and therefore results of multivariate or survival analysis will not be statistically correct or interpretable in current ED and TRI Technologies cohorts.

Future research should therefore explore patient- and prosthesis-related factors that increase the risk of leaflet escape, performed in large groups of patients in order to make a similar algorithm for ED or TRI Technologies valve patients. Until then, routine replacement of ED or TRI Technologies heart valves in asymptomatic patients with good-functioning valves on echocardiography cannot be recommended.

7 | CONCLUSIONS

Clinicians should be aware of the possibility of leaflet instability in patients with prosthetic heart valves, especially with ED and Edwards TEKNA valves. In these patients presenting with symptoms of sudden acute decompensated heart failure or cardiogenic shock, valve dysfunction should be strongly suspected, and we recommend angiography or transthoracic echocardiography and emergency surgery when leaflet escape is present. Further research for detection of cavitations and risk factors that make asymptomatic patients prone to leaflet escape in ED and Edwards TEKNA valves is needed to identify possible high-risk cases for valve fractures and to develop guidelines for prophylactic valve replacement.

ORCID

Gjis G.J. van Steenbergen http://orcid.org/0000-0003-0411-7014

REFERENCES

1. Blot WJ, Ibrahim MA, Ivey TD, et al. Twenty-five-year experience with the Björk-Shiley convexoconcave heart valve. a continuing clinical concern. Circulation. 2003;111:2850–2857.
2. Bottio T, Casarotto D, Thiene G, et al. Leaflet escape in a new bileaflet mechanical valve: TRI Technologies. Circulation. 2003;107:2303–2306.
3. Dikmengil M, Sucu N, Aytaçoglu BN, Mavioglu I. Leaflet escape in a TRI bileaflet rotatable mitral valve. J Heart Valve Dis. 2004;13:638–640.
4. Gerosa G, Carta R, Montisci M, et al. How to deal with recipients of valves prone to structural failure in the 2000s: Padua experience with the TRI Technologies valve. Ann Thorac Surg. 2006;82:858–864.
5. Cianciulli TF, Lax JA, Saccheri MC, et al. Acute mitral valve dysfunction due to a leaflet escape in a TRI-Bioteam bileaflet mechanical valve. J Echocardiogr. 2007;8:63–66.
6. Zhang H, Deng X, Cianciulli TF, et al. Pivoting system fracture in a bileaflet mechanical valve: a case report. J Biomed Mater Res B Appl Biomater. 2009;90:952–961.
7. Della Barbera M, Bottio T, Angelini A, et al. The pathology of TRI-Tech valve leaflet escape. J Heart Valve Dis. 2012;21:241–246.
8. Cianciulli TF, Lax JA, Saccheri MC, et al. Retrieval of a leaflet escaped in a TRI-Bioteam bileaflet mechanical prosthetic valve. Eur J Echocardiogr. 2008;9:65–68.
9. Mastromarino P, Chello M, Bevacqua E, et al. Duromedics original prosthesis: what do we really know about diagnosis and mechanism of leaflet escape? Can J Cardiol. 2000;16:1269–1272.
10. Deuvaert FE, Devriendt J, Massaut J, et al. Leaflet escape of a mitral Duromedics prosthesis. Case report. Acta Chir Belg. 1989;89:15–18.
11. Klepetko W, Moritz A, Milzoch J, et al. Leaflet fracture in Edwards-Duromedics bileaflet valves. J Thorac Cardiovasc Surg. 1989;97:90–94.
12. Kumar N, Balasundaram S, Rickard M, et al. Leaflet embolisation from Duromedics valves: a report of two cases. Thorac Cardiovasc Surg. 1991;39:382–383.
13. Baumgartner FJ, Munro Al, Jamieson WR. Fracture embolization of a Duromedics mitral prosthesis. Tex Heart Inst J. 1997;24:122–124.
14. Podesser BK, Khuei-Brady G, Eigenbauer E, et al. Long-term results of heart valve replacement with the Edwards Duromedics bileaflet prosthesis: a prospective ten-year clinical follow-up. J Thorac Cardiovasc Surg. 1998;115:1121–1129.
15. Hemmer WB, Doss M, Hannekum A, Kapfer X. Leaflet escape in a TEKNA and an original Duromedics bileaflet valve. Ann Thorac Surg. 2000;69:942–944.
16. Sudo K, Sasagawa N, Ide H, et al. Late leaflet fracture and embolization of a Duromedics mitral prosthesis. Jpn J Thorac Cardiovasc Surg. 2000;48:520–523.
17. Christiansen S, Scheld HH, Hammel D. Leaflet escape in a Tekna valve in aortic position. Ann Thorac Surg. 2001;71:761.
18. Jazayeri S, Meunier JP, Tatou E, et al. Fracture embolization of a Tekna mitral prosthesis: case report. J Heart Valve Dis. 2003;10:219–221.
19. L'Huillier J, Meunier JP, Jazayeri S. Acute mitral valve dysfunction: a new case of leaflet escape. Heart. 2001;85:513.
20. Tatou E, Saleh M, Eicher C, et al. Fracture-embolization of Duromedics valve prosthesis and microscopic uncommon lesions. Ann Thorac Surg. 2001;71:1366–1369.
21. Youn YN, Yoo KJ. Valve leaflet escape of Edwards Duromedics mechanical valve. Korean J Thorac Cardiovasc Surg. 2002;35:60–63.
22. Mert M, Ozkara A, Hatemi A. Leaflet escape in a revised Edwards-Duromedics mitral prostheses. J Heart Valve Dis. 2003;12:513–515.
23. Pfeiffer H, Bertolini J, Scheld HH, Brinkmann B. Fatal leaflet escape in an Edwards TEKNA aortic prosthesis. J Heart Valve Dis. 2006;15:97–99.
24. Fraguolis S, Palatianos GM. Fractured prosthetic valve leaflet. Eur J Cardiothorac Surg. 2008;34:907.
25. Yamazaki N, Yamashita K, Iwakura A, et al. Fracture embolization of an Edwards-Duromedics valve with asymmetrical closure. Asian Cardiovasc Thorac Ann. 2008;16:242–245.
26. Collison SP, Mishra YK. Leaflet escape in a modern mechanical heart valve: structure and cavitation. Heart. 2010;96:994.
27. Kim D, Hun SS, Cho U, et al. Prosthetic mitral valve leaflet escape. J Cardiovasc Ultrasound. 2013;21:96–99.
28. Kobayashi Y, Sano M, Mouru H, et al. Unilateral pulmonary edema due to leaflet fracture of a Duromedics Edwards bileaflet mitral valve. J Cardiovasc Anim Anesth. 2017;31:e16–e17.
29. Johansen P, Andersen TS, Hasenkam JM, et al. Mechanical heart valve cavitation in patients with bileaflet valves. J Thorac Cardiovasc Surg. 2004;125:513–515.
30. Kornberg A, Wildhirt SM, Schulze C, Kreuzer E. Leaflet escape in an Omnicarbon monoleaflet valve. Eur J Cardiothorac Surg. 2000;15:97–99.
31. Mosterd A, Shahin GM, van Boven WJ, et al. Images in cardiovascular medicine. Leaflet fracture of a St. Jude mechanical bileaflet valve. Circulation. 2005;111:e280–e281.
32. Kageyama S, Yoshioka D, Kawasumi R, et al. Sudden haemodynamic collapse caused by leaflet escape of the contemporary On-X mechanical valve. Eur J Cardiothorac Surg. 2018;54:608.
33. van Neer PLMJ. 2006. The Björk-Shiley valve: detecting broken struts using standard diagnostic ultrasound instruments (master thesis, Radboud University, Nijmegen, the Netherlands).

34. Baudet E, Roques X, McBride J, et al. A 8-year follow-up of the Edwards-Duromedics bileaflet prosthesis. J Cardiovasc Surg (Torino). 1995;36:437–442.

35. Johansen P. Mechanical heart valve cavitation. Expert Rev Med Devices. 2004;1:95–104.

36. Richard G, Beavan A, Strzepa P. Cavitation threshold ranking and erosion characteristics of bileaflet heart valve prostheses. J Heart Valve Dis. 1994;3:594–101.

37. Andersen TS, Johansen P, Paulsen PK, et al. Indication of cavitation in mechanical heart valve patients. J Heart Valve Dis. 2003;12:790–796.

38. van der Graaf Y, de Waard F, van Herwerden LA, Defauw J. Risk of strut fracture of Björk-Shiley valves. Lancet. 1992;339:257–261.

39. Kallewaard M, Algra A, Defauw J, et al. Long-term survival after valve replacement with Björk-Shiley CC valves. Am J Cardiol. 2000;85:598–603.

40. van Gorp MJ, Steyerberg EW, van der Graaf Y. Decision guidelines for prophylactic replacement of Björk-Shiley convexo-concave heart valves: impact on clinical practice. Circulation. 2004;109:2092–2096.

41. Steyerberg EW, Kallewaard M, van der Graaf Y, et al. Decision analyses for prophylactic replacement of the Björk-Shiley convexo-concave heart valve: an evaluation of assumptions and estimates. Med Decis Making. 2000;20:20–32.

How to cite this article: van Steenbergen GG, Tsang QH, van der Heide SM, Verkroost MW, Li WW, Morshuis WJ. Spontaneous leaflet fracture resulting in embolization from mechanical valve prostheses. J Card Surg. 2019;34:124–130. https://doi.org/10.1111/jocs.13975